The Finnish medical device company Finnsusp is conquering global markets together with its trusted partners. A new factory, investments in equipment and personnel, and persistent product development are laying the foundation for doubling revenue within the next few years.
The Finnish company Finnsusp is experiencing an exciting phase. The company specialises in contact lens solutions and dry eye products and is currently pursuing an investment project worth approximately six million euros. The new factory building is already in operation, while the existing facilities are being renovated to meet future needs.
In the summer of 2026, a new aseptic filling line for dry eye products will be launched. According to CEO Riikka Järvinen, it will increase the company’s production capacity fivefold, accelerating the company’s international growth.
Part of the investments are co-funded by ELY Centre and the European Union’s European Regional Development Fund (ERDF). However, the majority of the investments are made using the family- and employee-owned company’s own funds.
The risk is substantial. Nevertheless, Järvinen looks to the future with confidence.
– We have premium products, highly skilled staff and excellent partners. Faith in the future is strong, she says.
The company has shifted its focus entirely to contact lens solutions and dry eye products, which have the potential for international growth. In the summer of 2025, Finnsusp sold its eyeglass lens business to the Finnish technology company IXI Eyewear, which develops intelligent eyewear.
Innovation at the Core of the Business
Research, development and innovation lie at the heart of Finnsusp. The company was founded in the 1970s based on customer needs and a product development idea.
Contact lenses had only recently appeared on the market and Järvinen’s optician parents noticed that they irritated their customers’ eyes. They believed the issue was with the contact lens solutions, so they teamed up with chemist friends to create products that nurture both eyes and lenses.
– This approach has brought us to where we are today. We develop all the products we sell ourselves, and continuous product development is a core priority, Järvinen says.
Finnsusp’s products are sold in highly competitive markets across more than 35 countries in Europe, the Middle East, Africa, and both South and North America. Järvinen believes their success stems from the products’ uniqueness and their strong performance in international studies.
Finnsusp’s latest innovation is a microemulsion-based eye drop called Puro Suoja, designed to break the vicious cycle of dry eyes. Its formulation and manufacturing process are patented.
– Emulsion-based products are usually cloudy, but this one is clear, meaning it does not blur vision, Järvinen explains.
Growing Alongside Partners
The majority of Finnsusp’s products are exported. Partners include major pharmaceutical companies and wholesalers with established distribution channels.
In Finland, Finnsusp is known for its brands Piiloset and Puro. The company’s export business is largely under customer brands. For example, many pharmaceutical companies have a portfolio of prescription eye medications, but they lack over-the-counter eye care products.
– We can expand their portfolio instead of them having to produce dry eye products themselves, Sales Director Markus Tenovuo says.
He emphasises the importance of research when entering new markets. Before signing a distribution deal, it’s essential to evaluate the partner: do they know the market, can they sell the products, and what value does the collaboration bring to both sides?
– Much of it comes down to the people involved. When values don’t match, cooperation is challenging, Järvinen adds.
At Finnsusp, international trade risks are managed through broad diversification. Tenovuo notes that all customers are equally important, with partners in five continents.
Advancing with Ambition
The growth of Finnsusp’s exports is carefully managed. Despite inquiries, the company has not yet entered markets such as China or Australia. First, it ensures that production capacity is sufficient to meet demand properly.
– In many markets, product registrations are costly and can take years. Significant business must therefore be generated to justify the effort, Järvinen says.
The growth targets for the coming years are ambitious. Järvinen aims to at least double the company’s current 12-million-euro turnover by 2030.
– The most important thing is to grow profitably. This enables investments in both equipment and personnel, Tenovuo adds.
Meanwhile, research and development at Finnsusp’s lab goes on, with the next new products expected to be revealed in 2027.
Text and pictures: Heidi Pelander